These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38796180)

  • 1. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
    David P; Hen O; Ben-Shabbat N; Macleod T; Amital H; Watad A; McGonagle DG
    RMD Open; 2024 May; 10(2):. PubMed ID: 38796180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
    Praveen D; Puvvada RC; M VA
    Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.
    Abizanda P; Calbo Mayo JM; Mas Romero M; Cortés Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Campayo Escolano C; Ochoa Serrano A; Sánchez-Flor Alfaro V; López Bru R; Gómez Ballesteros C; Caldevilla Bernardo D; Callejas González FJ; Andrés-Pretel F; Lauschke VM; Stebbing J
    J Am Geriatr Soc; 2021 Oct; 69(10):2752-2758. PubMed ID: 34235720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
    Troyer BS; Kovacic Scherrer N; Garavaglia J
    J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
    Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
    EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
    N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
    Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
    Spinelli FR; Conti F; Gadina M
    Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
    Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
    Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
    Lin Z; Niu J; Xu Y; Qin L; Ding J; Zhou L
    J Med Virol; 2022 Apr; 94(4):1523-1534. PubMed ID: 34846766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
    Hasan MJ; Rabbani R; Anam AM; Huq SMR; Polash MMI; Nessa SST; Bachar SC
    BMC Infect Dis; 2021 May; 21(1):427. PubMed ID: 33962573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
    Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M;
    Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
    Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
    J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit.
    Ferro F; La Rocca G; Elefante E; Italiano N; Moretti M; Talarico R; Pelati E; Valentini K; Baldini C; Mozzo R; De Simone L; Mosca M
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.